These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

790 related items for PubMed ID: 17437808

  • 1. Patterns of local failure following prostate brachytherapy.
    Stone NN, Stock RG, White I, Unger P.
    J Urol; 2007 May; 177(5):1759-63; duscussion 1763-4. PubMed ID: 17437808
    [Abstract] [Full Text] [Related]

  • 2. Local control following permanent prostate brachytherapy: effect of high biologically effective dose on biopsy results and oncologic outcomes.
    Stone NN, Stock RG, Cesaretti JA, Unger P.
    Int J Radiat Oncol Biol Phys; 2010 Feb 01; 76(2):355-60. PubMed ID: 19632069
    [Abstract] [Full Text] [Related]

  • 3. Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer.
    Wong WW, Schild SE, Vora SA, Halyard MY.
    Int J Radiat Oncol Biol Phys; 2004 Sep 01; 60(1):24-9. PubMed ID: 15337536
    [Abstract] [Full Text] [Related]

  • 4. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
    Kupelian P, Kuban D, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A.
    Int J Radiat Oncol Biol Phys; 2005 Feb 01; 61(2):415-9. PubMed ID: 15667961
    [Abstract] [Full Text] [Related]

  • 5. Optimized prostate brachytherapy minimizes the prognostic impact of percent of biopsy cores involved with adenocarcinoma.
    Nurani R, Wallner K, Merrick G, Virgin J, Orio P, True LD.
    J Urol; 2007 Nov 01; 178(5):1968-73; discussion 1973. PubMed ID: 17868717
    [Abstract] [Full Text] [Related]

  • 6. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A, Kuban D.
    Int J Radiat Oncol Biol Phys; 2005 Nov 01; 63(3):795-9. PubMed ID: 15925452
    [Abstract] [Full Text] [Related]

  • 7. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
    Lee AK, Levy LB, Cheung R, Kuban D.
    Int J Radiat Oncol Biol Phys; 2005 Oct 01; 63(2):456-62. PubMed ID: 15927415
    [Abstract] [Full Text] [Related]

  • 8. Changing the patterns of failure for high-risk prostate cancer patients by optimizing local control.
    Stock RG, Ho A, Cesaretti JA, Stone NN.
    Int J Radiat Oncol Biol Phys; 2006 Oct 01; 66(2):389-94. PubMed ID: 16965991
    [Abstract] [Full Text] [Related]

  • 9. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer.
    Potters L, Morgenstern C, Calugaru E, Fearn P, Jassal A, Presser J, Mullen E.
    J Urol; 2005 May 01; 173(5):1562-6. PubMed ID: 15821486
    [Abstract] [Full Text] [Related]

  • 10. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy.
    Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen Z, Lief JH, Adamovich E.
    Urology; 2005 Jan 01; 65(1):95-100. PubMed ID: 15667872
    [Abstract] [Full Text] [Related]

  • 11. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy.
    Merrick GS, Butler WM, Wallner KE, Galbreath RW, Lief JH, Allen Z, Adamovich E.
    Int J Radiat Oncol Biol Phys; 2005 Jan 01; 61(1):32-43. PubMed ID: 15629591
    [Abstract] [Full Text] [Related]

  • 12. Lack of benefit of pelvic radiation in prostate cancer patients with a high risk of positive pelvic lymph nodes treated with high-dose radiation.
    Vargas CE, Galalae R, Demanes J, Harsolia A, Meldolesi E, Nürnberg N, Schour L, Martinez A.
    Int J Radiat Oncol Biol Phys; 2005 Dec 01; 63(5):1474-82. PubMed ID: 15964706
    [Abstract] [Full Text] [Related]

  • 13. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features.
    Vargas C, Martínez A, Galalae R, Demanes J, Harsolia A, Schour L, Nuernberg N, Gonzalez J.
    Prostate Cancer Prostatic Dis; 2006 Dec 01; 9(3):245-53. PubMed ID: 16786040
    [Abstract] [Full Text] [Related]

  • 14. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
    Teh BS, Ayala G, Aguilar L, Mai WY, Timme TL, Vlachaki MT, Miles B, Kadmon D, Wheeler T, Caillouet J, Davis M, Carpenter LS, Lu HH, Chiu JK, Woo SY, Thompson T, Aguilar-Cordova E, Butler EB.
    Int J Radiat Oncol Biol Phys; 2004 Apr 01; 58(5):1520-9. PubMed ID: 15050332
    [Abstract] [Full Text] [Related]

  • 15. Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy.
    Eggener SE, Roehl KA, Yossepowitch O, Catalona WJ.
    J Urol; 2006 Oct 01; 176(4 Pt 1):1399-403. PubMed ID: 16952643
    [Abstract] [Full Text] [Related]

  • 16. Effect of cigarette smoking on biochemical outcome after permanent prostate brachytherapy.
    Merrick GS, Butler WM, Wallner KE, Galbreath RW, Lief JH, Adamovich E.
    Int J Radiat Oncol Biol Phys; 2004 Mar 15; 58(4):1056-62. PubMed ID: 15001245
    [Abstract] [Full Text] [Related]

  • 17. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer.
    Crook J, Ludgate C, Malone S, Lim J, Perry G, Eapen L, Bowen J, Robertson S, Lockwood G.
    Int J Radiat Oncol Biol Phys; 2004 Sep 01; 60(1):15-23. PubMed ID: 15337535
    [Abstract] [Full Text] [Related]

  • 18. Long-term outcomes in younger men following permanent prostate brachytherapy.
    Shapiro EY, Rais-Bahrami S, Morgenstern C, Napolitano B, Richstone L, Potters L.
    J Urol; 2009 Apr 01; 181(4):1665-71; discussion 1671. PubMed ID: 19233394
    [Abstract] [Full Text] [Related]

  • 19. Combined modality treatment in the management of high-risk prostate cancer.
    Stock RG, Cahlon O, Cesaretti JA, Kollmeier MA, Stone NN.
    Int J Radiat Oncol Biol Phys; 2004 Aug 01; 59(5):1352-9. PubMed ID: 15275720
    [Abstract] [Full Text] [Related]

  • 20. Permanent interstitial brachytherapy in younger patients with clinically organ-confined prostate cancer.
    Merrick GS, Butler WM, Wallner KE, Galbreath RW, Adamovich E.
    Urology; 2004 Oct 01; 64(4):754-9. PubMed ID: 15491715
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.